Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort studyChristopher M. Clark, Daniel Skovronsky, Anupa Arora et al.|The Lancet Neurology|2012Cited by 846
Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal agingKeith A. Johnson, Reisa A. Sperling, Christopher Gidicsin et al.|Alzheimer s & Dementia|2013Cited by 265
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive declineP. Murali Doraiswamy, Reisa A. Sperling, Robert E. Coleman et al.|Neurology|2012Cited by 228
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer diseaseAdam Fleisher, Eric M. Reiman, Kewei Chen et al.|Neurobiology of Aging|2012Cited by 210
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living FacilitiesMyron S. Cohen, Jason Morris, Ajay Nirula et al.|JAMA|2021Cited by 208